Impact on abiraterone pharmacokinetics (PK) and safety: Open-label drug-drug interaction (DDI) studies with ketoconazole and rifampicin

被引：0
|
作者：
Chien, C. [1 ]
Bernard, A. [2 ]
Vaccaro, N. [3 ]
Acharya, M. [2 ]
Jiao, J. [4 ]
Monbaliu, J. [5 ]
De Vries, R. [6 ]
Stieltjes, H. [6 ]
Yu, M. K. [7 ]
Tran, N. P. [7 ]
机构：
[1] Janssen Res & Dev, Clin Pharmacol, Titusville, NJ USA
[2] Janssen Res & Dev, Clin Pharmacol, Raritan, NJ USA
[3] Janssen Res & Dev, Clin Pharmacol, San Diego, CA USA
[4] Janssen Res & Dev, Biometr & Reporting, Raritan, NJ USA
[5] Janssen Res & Dev, Preclin Project Dev, Beerse, Belgium
[6] Janssen Res & Dev, Bioanal, Beerse, Belgium
[7] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2917
引用
收藏
页码：S702 / S703
页数：2
相关论文
共 50 条
  • [21] Best Practices for the Use of Itraconazole as a Replacement for Ketoconazole in Drug-Drug Interaction Studies
    Liu, Lichuan
    Bello, Akintunde
    Dresser, Mark J.
    Heald, Donald
    Komjathy, Steven Ferenc
    O'Mara, Edward
    Rogge, Mark
    Stoch, S. Aubrey
    Robertson, Sarah M.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (02): : 143 - 151
  • [22] Synthesis of stable isotopically labelled internal standards for drug-drug interaction (DDI) studies
    Zimmermann, J.
    Allen, J.
    Atzrodt, J.
    De-Bruin, B.
    Derdau, V.
    Gantz, D.
    Herbert, J.
    Raddatz, S.
    Roy, S.
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (13-14): : 1277 - 1278
  • [23] Synthesis of stable isotope labelled internal standards for drug-drug interaction (DDI) studies
    Atzrodt, J.
    Blankenstein, J.
    Brasseur, D.
    Calvo-Vicente, S.
    Denoux, M.
    Derdau, V.
    Lavisse, M.
    Perard, S.
    Roy, S.
    Sandvoss, M.
    Schofield, J.
    Zimmermann, J.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (18) : 5658 - 5667
  • [24] Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial
    Atwine, Daniel
    Baudin, Elisabeth
    Gele, Thibaut
    Muyindike, Winnie
    Mworozi, Kenneth
    Kyohairwe, Racheal
    Kananura, Keneth
    Orikiriza, Patrick
    Nyehangane, Dan
    Nanjebe, Deborah K. T.
    Furlan, Valerie
    Verstuyft, Celine
    Barrail-Tran, Aurelie
    Taburet, Anne-Marie
    Bonnet, Maryline
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (05) : 1250 - 1258
  • [25] No Relevant Pharmacokinetic (PK) Interaction between Rezafungin and Nine Probe Drugs: Results from a Drug-Drug Interaction (DDI) Study
    Ong, Voon
    Sandison, Taylor
    Flanagan, Shawn
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [26] Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug-Drug Interaction Study in Healthy Male Korean Volunteers
    Noh, Yook-Hwan
    Lim, Hyeong-Seok
    Jin, Seok-Joon
    Kim, Mi Jo
    Kim, Yo Han
    Sung, Hye Ryoung
    Choi, Hee Youn
    Bae, Kyun-Seop
    [J]. CLINICAL THERAPEUTICS, 2012, 34 (05) : 1182 - 1194
  • [27] Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers
    Banankhah, Peymaan S.
    Garnick, Kyle A.
    Greenblatt, David J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (10): : 1196 - 1202
  • [28] Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study
    Italo Poggesi
    Lilian Y. Li
    James Jiao
    Peter Hellemans
    Freya Rasschaert
    Loeckie de Zwart
    Jan Snoeys
    Marc De Meulder
    Rao N. V. S. Mamidi
    Daniele Ouellet
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45 : 101 - 111
  • [29] Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study
    Venkatakrishnan, Karthik
    Rader, Michael
    Ramanathan, Ramesh K.
    Ramalingam, Suresh
    Chen, Eric
    Riordan, William
    Trepicchio, William
    Cooper, Michael
    Karol, Michael
    von Moltke, Lisa
    Neuwirth, Rachel
    Egorin, Merrill
    Chatta, Gurkamal
    [J]. CLINICAL THERAPEUTICS, 2009, 31 : 2444 - 2458
  • [30] A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SIMULATION OF NALOXEGOL PHARMACOKINETICS AND DRUG-DRUG INTERACTION (DDI) POTENTIAL
    Zhou, D.
    Bui, K.
    Sostek, M.
    Al-Huniti, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S53 - S53
12345